A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found. The “striking” findings showed an ...

Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without sacrificing quality of life in prostate cancer. In patients with high-risk ...

WASHINGTON - There's more advice on the contentious issue of prostate cancer screening: A leading group of cancer specialists says the decision hinges in part on a man's life expectancy. Doctors ...

Patients with nonmetastatic prostate cancer are more likely to die from other causes than from cancer when treated per guidelines. The 15-year cancer mortality risk is 5.5% for low-risk and 22% for ...

Most men who are treated for prostate cancer according to modern guidelines have good survival rates and the majority of these men will die of causes other than prostate cancer. This is revealed in a ...

Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, talazoparib, which has been approved for NHS use. The once-daily pill, with its ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

A life-extending prostate cancer drug is to be made available to thousands of men in England in a matter of weeks, after a campaign by a patient and a charity. Abiraterone has been provided on the NHS ...

Add Yahoo as a preferred source to see more of our stories on Google. The once-daily pill, with its brand name Talzenna and produced by Pfizer, offers a crucial at-home treatment option after ...